ReviewTrends in immunology2013
Mechanisms of peptide repertoire selection by HLA-DM.
Review in Trends in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 54 citations in OpenAlex.
- A Comprehensive HLA-DR4 MHC Class II Tetramer Platform for the Detection and Functional Validation of Post-Translational Modification Neoantigens.International journal of molecular sciences · 2026Article
- Mechanisms of and mitigating strategies for cellular immune responses to CRISPR-associated nucleases in genome editing therapy.Frontiers in medicine · 2026Review
- Predictive value of MHC-related genes in cervical cancer: implications for immunotherapy and prognostic nomogram development.Discover oncology · 2025Article
- The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer.Discover oncology · 2024Review
- An immunoinformatic approach to assessing the immunogenic capacity of alpha-neurotoxins in elapid snake venoms.Frontiers in pharmacology · 2023Article
- Type 2 cytokines in the thymus activate SirpαNature immunology · 2022Article
- T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy.Frontiers in immunology · 2022Review
- New vistas unfold: Chicken MHC molecules reveal unexpected ways to present peptides to the immune system.Frontiers in immunology · 2022Review
- Partnering for the major histocompatibility complex class II and antigenic determinant requires flexibility and chaperons.Current opinion in immunology · 2021Review
- Structural Comparison Between MHC Classes I and II; in Evolution, a Class-II-Like Molecule Probably Came First.Frontiers in immunology · 2021Article
- Integrated Analysis of lncRNAs, mRNAs, and TFs to Identify Regulatory Networks Underlying MAP Infection in Cattle.Frontiers in genetics · 2021Article
- Type 1 Diabetes and Autoimmune Thyroid Disease-The Genetic Link.Frontiers in endocrinology · 2021Review
- MS-Based HLA-II Peptidomics Combined With Multiomics Will Aid the Development of Future Immunotherapies.Molecular & cellular proteomics : MCP · 2021Review
- Impact of HLA-DR Antigen Binding Cleft Rigidity on T Cell Recognition.International journal of molecular sciences · 2020Article
- Human Hepatitis B Viral Infection Outcomes Are Linked to Naturally Occurring Variants ofJournal of immunology (Baltimore, Md. : 1950) · 2020Article
- Peptide Epitope Hot Spots of CD4 T Cell Recognition Within Influenza Hemagglutinin During the Primary Response to Infection.Pathogens (Basel, Switzerland) · 2019Article
- Ancient features of the MHC class II presentation pathway, and a model for the possible origin of MHC molecules.Immunogenetics · 2019Review
- HLA-DO Modulates the Diversity of the MHC-II Self-peptidome.Molecular & cellular proteomics : MCP · 2019Article
- Class II MHC antigen processing in immune tolerance and inflammation.Immunogenetics · 2019Review
- The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules.Annual review of immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Recently, crystal structures of key complexes in antigen presentation have been reported. HLA-DM functions in antigen presentation by catalyzing dissociation of an invariant chain remnant from the peptide binding groove and stabilizing empty MHC class II proteins in a peptide-receptive conformation. The crystal structure of a MHC class II-HLA-DM complex explains how HLA-DM stabilizes an otherwise short-lived transition state and promotes a rapid peptide exchange process that favors the highest-affinity ligands. HLA-DO has sequence similarity with MHC class II molecules yet inhibits antigen presentation. The structure of the HLA-DO-HLA-DM complex shows that it blocks HLA-DM activity as a substrate mimic. Alterations in the efficiency of DM-mediated peptide selection may contribute to autoimmune pathologies, which will be an exciting area for future investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.